Table III.

Localization of NF-κB in immature HMC-1 cells

Conditionsan% Cytoplasmicb% Perinuclear% Nuclear% Nuclear + % Perinuclear
Untreated361100 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
48/8035092.0 ± 2.38.0 ± 2.30.0 ± 0.08.0 ± 2.3
48/80+ Zn34295.9 ± 0.64.1 ± 0.60.0 ± 0.04.1 ± 0.6
IgE/Anti-IgE21792.1 ± 3.16.0 ± 3.32.0 ± 2.07.9 ± 3.1
IgE/Anti-IgE+ Zn32997.3 ± 0.42.7 ± 0.40.0 ± 0.02.7 ± 0.4
TNF-α3913.6 ± 3.6**3.6 ± 0.792.8 ± 2.9**96.4 ± 3.6**
TNF-α+ Zn31897.4 ± 2.6**2.6 ± 2.60.0 ± 0.0**2.6 ± 2.6**
TPEN3726.8 ± 0.3**22.3 ± 0.9**70.9 ± 1.1**93.2 ± 0.3**
TPEN+ Zn34587.1 ± 5.4**5.8 ± 3.6*7.2 ± 3.0**12.9 ± 5.4**
  • a Cells were treated with 48/80 (1 μg/ml, 18 h), IgE (5 μg/ml for 18 h), followed by anti-IgE (1/5000 for 2 h), TNF (20 ng/ml for 4 h), or no addition (for 18 h).

  • b Data are expressed as percentage of total (mean ± SEM).

  • *One-way ANOVA analysis was used in conjunction with the post hoc Tukey HSD test, p < 0.05 and **, p < 0.005: asterisks alongside SEM indicate comparisons between untreated and corresponding treated cells for each pattern of labeling, while those beneath the SEM refer to comparisons between with and without Zn treatment.